AstraZeneca’s Covid-19 antibody treatment failed to meet its main targets in its latest trial, while showing it could prevent people exposed to the virus from developing the disease if given early enough. The phase 3 trial of the AZD7442 treatment found that it was not significantly more effective than a placebo. The treatment is separate from the company’s vaccines, which are being used worldwide to protect against coronavirus. AstraZeneca has agreed to supply up to 700,000 doses of the antibody treatment to the US government, worth up to $726 million (€598 million). Antibody treatments from companies including Regeneron and Eli Lilly have been used to bolster the immune response of patients with Covid-19.

Source: The Irish Times June 15, 2021 18:56 UTC